Value
7.4/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 5.0 |
| Analyst target | 9.0 |
- ▸Attractively valued
FDMT · Why this verdict
Why 4D Molecular Therapeutics (FDMT) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.3/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
4D Molecular Therapeutics is a cash-burning clinical-stage biotech with minimal recurring revenue, heavy insider selling (0.527% of market cap) and 23% short interest, offset by a $24.44 analyst target that is 126.3% above the $10.80 price.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Quality scores 2.5, below the 4.0 minimum, with free cash flow at -99% of revenue and ROE and ROA both at 0.0. Quality breakdown | Cash burn should be funded without dilution and quality rise above 4.0 as revenue builds. | →Stable |
| CounterClinical-stage biotechs are expected to burn cash ahead of data; the value rests on pipeline results that these scores do not measure. | ||
Quarterly revenue is tiny and lumpy: $3.8M in June 2026 and $3.0M in March 2026, versus $85.1M in December 2025 and $0.0 in early 2025. Revenue quarters | Quarterly revenue should stay above $3M, matching the $3.1M estimate for next quarter. | ↓Deteriorating |
| CounterThe December 2025 figure likely reflects a one-time collaboration payment, so recurring revenue may be lower than any trend suggests. | ||
Insiders sold $3.14M of stock in 90 days across 12 sales, equal to 0.527% of market cap, with no buys. Insider | Insider net selling should fall below 0.2% of market cap in the next two quarters. | →Stable |
| CounterFrequent small sales by executives are often pre-scheduled and unrelated to the trial outlook, and institutions are accumulating. | ||
The $24.44 analyst target is 126.3% above the $10.80 price against 15.0% downside, a reward-to-risk of 8.42, with analyst upside noted at 160%. Upside pct | Price should rise toward the analyst target as clinical milestones are met. | →Stable |
| CounterTargets for binary biotech outcomes are speculative, implied volatility is 200%, and 23% short interest signals real doubt. | ||
Quality scores 2.5, below the 4.0 minimum, with free cash flow at -99% of revenue and ROE and ROA both at 0.0.
→StableQuality breakdown
- Expectation
- Cash burn should be funded without dilution and quality rise above 4.0 as revenue builds.
CounterClinical-stage biotechs are expected to burn cash ahead of data; the value rests on pipeline results that these scores do not measure.
Quarterly revenue is tiny and lumpy: $3.8M in June 2026 and $3.0M in March 2026, versus $85.1M in December 2025 and $0.0 in early 2025.
↓DeterioratingRevenue quarters
- Expectation
- Quarterly revenue should stay above $3M, matching the $3.1M estimate for next quarter.
CounterThe December 2025 figure likely reflects a one-time collaboration payment, so recurring revenue may be lower than any trend suggests.
Insiders sold $3.14M of stock in 90 days across 12 sales, equal to 0.527% of market cap, with no buys.
→StableInsider
- Expectation
- Insider net selling should fall below 0.2% of market cap in the next two quarters.
CounterFrequent small sales by executives are often pre-scheduled and unrelated to the trial outlook, and institutions are accumulating.
The $24.44 analyst target is 126.3% above the $10.80 price against 15.0% downside, a reward-to-risk of 8.42, with analyst upside noted at 160%.
→StableUpside pct
- Expectation
- Price should rise toward the analyst target as clinical milestones are met.
CounterTargets for binary biotech outcomes are speculative, implied volatility is 200%, and 23% short interest signals real doubt.
Per-dimension breakdown
Quality
2.5/10data confidence 86%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 5.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -99% of revenue
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 3.8 |
| OBV | 10.0 |
| MA position | 7.0 |
| Volume | 4.3 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
8.1/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.3 |
| Price target | 10.0 |
| erm sentiment | 5.5 |
- ▸Analyst upside: 117%
Insider
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 10.0 |
| notable moves | 5.0 |
- ▸Notable insider selling — $3,143,587 (0.440% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.9 |
| quality rank | 1.6 |
| growth rank | 10.0 |
- ▸Industry growth leader
Technical
4.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 3.7 |
| support resistance | 4.2 |
| 52w position | 5.3 |
Risk (lower is worse)
3.1/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.1 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| beta | 0.9 |
| debt equity | 9.6 |
- ▸High short interest justified: 24%
- ▸High IV: 176%
Catalyst
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 1.1 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Earnings concerns: 1B/2M
- ▸Earnings in 12 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (6)
- MOMENTUM:6.1>=5.5
- ASYMMETRY:5.9>=1.5
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- INSIDER:0.44%=HEAVY
Warning (1)
- EARNINGS_PROXIMITY:12d<=14d (soft)
Reward-to-Risk
5.93
Upside
+89.0%
Downside
15.0%
Sizing output
AVOID
SetupRange Bound — RSI 51 mid-range, Bollinger mid-band
EdgeInst Constrain — Small cap ($0.7B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the INSIDER gate's 0.44%=HEAVY outcome against Sentiment at 8.1 and asymmetric R:R of 5.93.
The strongest dimensions are Sentiment at 8.1, Value at 7.4, and Momentum at 6.1; the weakest are Quality at 2.5, Risk (lower is worse) at 3.1, and Technical at 4.4. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 5.93 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Cash Burn Weak Quality
Trip ifFree cash burn exceeds 150% of revenue.
- P2Lumpy Collaboration Revenue
Trip ifQuarterly revenue falls below $2M.
- P3Heavy Insider Selling
Trip ifInsider net selling exceeds 1% of market cap over 90 days.
- P4Large Analyst Upside
Trip ifShare price drops to $10.36 or lower, the stop-loss level, from the current $10.80.